Progress of vimentin in hepatocellular carcinoma

Abstract

Abstract: Epithelial-mesenchymal transition (EMT) is a critical mechanism related to invasion, metastasis and drug resistance. Vimentin(VIM), as the biomarker of EMT, functions in regulating EMT and forms epithelial-like cancer stem cells and itself methylation, and exosomes excrete VIM directly or indirectly, which leads to invasiveness and proliferation, chemotherapy resistance and postoperative recurrence of HCC. Importantly, combine detection of circulating VIM and AFP level in patients' serum samples, significantly improved the sensitivity and specificity for diagnosis of HCC, and predict poor prognosis.

Key words: vimentin, cancer stem cells, VIM methylation, exosomes

CLC Number:

R735.7

DONG Bao-long, HAN Cai-wen, SHI Ming, ZHENG Wen-xue, YANG Xiao-jun. Progress of vimentin in hepatocellular carcinoma[J]. Basic & Clinical Medicine, 2020, 40(2): 238-242.

References

[1]Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer, 2019, 144: 1941-1953.
[2]Akinyemiju T, Abera S, Ahmed MM, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015[J]. JAMA Oncol, 2017,3:1683-1691.
[3]Brabletz T, Kalluri R, Nieto MA, et al. EMT in cancer[J]. Nat Rev Cancer,2018,18:128-134.
[4]Cho ES, Kang HE, Kim NH, et al. Therapeutic implications of cancer epithelial-mesenchymal transition (EMT)[J]. Arch Pharm Res, 2019,42:14-24.
[5]Huang R, Zong X. Aberrant cancer metabolism in epithelial-mesenchymal transition and cancer metastasis: Mechanisms in cancer progression[J]. Crit Rev Oncol Hematol,2017, 115:13-22.
[6]Idriss NK, Fakhry M, Imam HM,et al. Analysis of lamin B1, vimentin and anti-ku86 as prospective biomarkers of hepatocellular carcinoma in patients with hepatitis C virus Infection[J]. Cell Physiol Biochem,2019, 52:595-605.
[7]Dong Q, Zhu X, Dai C, et al. Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin[J]. Oncotarget,2016,7:12997-13012.
[8]成超, 李海洋, 叶朝阳,等.波形蛋白在原发性肝癌组织中的表达及临床意义[J].重庆医学,2017,46: 4714-4717.
[9]Ghosh S, Ahrens Wa, Phatak Su, et al. Association of filamin A and vimentin with hepatitis C virus proteins in infected human hepatocytes[J]. J Viral Hepat,2011,18: e568-577.
[10]Pan TL, Wang PW, Huang CC, et al. Network analysis and proteomic identification of vimentin as a key regulator associated with invasion and metastasis in human hepatocellular carcinoma cells[J]. J Proteomics,2012, 75:4676-4692.
[11]Hu L, Ye H, Huang G, et al. Long noncoding RNA GAS5 suppresses the migration and invasion of hepatocellular carcinoma cells via miR-21[J]. Tumour Biol,2016,37:2691-2702.
[12]Zhu QS, Rosenblatt K, Huang KL, et al. Vimentin is a novel AKT1 target mediating motility and invasion[J]. Oncogene,2011, 30:457-470.
[13]Chen Z, Yu W, Zhou Q, et al. A Novel lncRNA IHS promotes tumor proliferation and metastasis in HCC by regulating the ERK- and AKT/GSK-3beta-signaling pathways[J]. Mol Ther Nucleic Acids,2019,16:707-720.
[14]Gramantieri L, Baglioni M, Fornari F, et al. LncRNAs as novel players in hepatocellular carcinoma recurrence[J]. Oncotarget,2018; 9:35085-35099.
[15]Chang L, Li C, Lan T, et al. Decreased expression of long non-coding RNA GAS5 indicates a poor prognosis and promotes cell proliferation and invasion in hepatocellular carcinoma by regulating vimentin[J]. Mol Med Rep, 2016, 13:1541-1550.
[16]Hodeib H, Elshora O, Selim A, et al. Serum midkine and osteopontin levels as diagnostic biomarkers of hepatocellular carcinoma[J]. Electron Physician,2017,9:3492-3498.
[17]Hou G, Zhao Q, Zhang M, et al. LSD1 regulates Notch and PI3K/Akt/mTOR pathways through binding the promoter regions of Notch target genes in esophageal squamous cell carcinoma[J]. Onco Targets Ther,2019, 12:5215-5225.
[18]Laisne M, Gupta N, Kirsh O, et al. Mechanisms of DNA methyltransferase recruitment in mammals[J]. Genes,2018. doi: 10.3390/genes9120617.
[19]Holmila R, Sklias A, Muller DC, et al. Targeted deep sequencing of plasma circulating cell-free DNA reveals Vimentin and Fibulin 1 as potential epigenetic biomarkers for hepatocellular carcinoma[J]. PLoS One, 2017, 12: e0174265. doi: 10.1371/journal.pone.0174265.
[20]Kitamura Y, Shirahata A, Sakuraba K, et al. Aberrant methylation of the Vimentin gene in hepatocellular carcinoma[J]. Anticancer Res,2011,31:1289-1291.
[21]Topcul M,Cetin I. Clinical significance of epithelial- mesenchymal transition and cancer stem cells[J].BUON,2016,21: 312-319.
[22]Mitra A, Satelli A, Xia X, et al. Cell-surface Vimentin: A mislocalized protein for isolating csVimentin (+) CD133(-) novel stem-like hepatocellular carcinoma cells expressing EMT markers[J]. Int J Cancer,2015, 137:491-496.
[23]徐先云, 严俊, 李汛. 外泌体在肝癌中的研究进展及应用前景[J]基础医学与临床, 2018, 38:107-111.
[24]Hu JL, Wang W, Lan XL, et al. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer[J]. Mol cancer,2019, 18:91. doi: 10.1186/s12943-019-1019-x.
[25]Chen L, Guo P, He Y, et al. HCC-derived exosomes elicit HCC progression and recurrence by epithelial-mesenchymal transition through MAPK/ERK signalling pathway[J]. Cell Death Dis,2018, 9:513. doi: 10.1038/s41419-018-0534-9.